Provided by Tiger Trade Technology Pte. Ltd.

Prelude Therapeutics Inc

3.56
-0.1800-4.81%
Post-market: 3.54-0.0200-0.56%19:55 EDT
Volume:676.36K
Turnover:2.44M
Market Cap:283.53M
PE:-4.96
High:3.90
Open:3.74
Low:3.43
Close:3.74
52wk High:6.83
52wk Low:1.16
Shares:79.64M
Float Shares:4.56M
Volume Ratio:1.88
T/O Rate:14.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7183
EPS(LYR):-1.2929
ROE:-57.73%
ROA:-27.15%
PB:2.12
PE(LYR):-2.75

Loading ...

Prelude Therapeutics reports Q2 EPS (14c), consensus (19c)

TIPRANKS
·
Aug 11

Prelude Therapeutics Q2 Revenue USD 5.704 Million

THOMSON REUTERS
·
Aug 11

Prelude Therapeutics Q2 EPS USD -0.14

THOMSON REUTERS
·
Aug 11

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
Aug 11

Prelude Therapeutics Incorporated Expected to Post a Loss of 20 Cents a Share - Earnings Preview

Reuters
·
Aug 10

Prelude Therapeutics Price Target Maintained with a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
Jul 29

Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline

TIPRANKS
·
Jul 28

Prelude Therapeutics Shareholders Back Leadership and Governance

TIPRANKS
·
Jun 11

Prelude Therapeutics shareholders elect three directors at annual meeting

Reuters
·
Jun 11

Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

TIPRANKS
·
May 15

Prelude Therapeutics (PRLD) Losses Narrow In Q1 2026 Challenging Bearish Narratives

Simply Wall St.
·
May 14

Prelude Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)

TIPRANKS
·
May 12

Prelude Therapeutics Q1 EPS $(0.13) Beats $(0.25) Estimate, Sales $4.580M

Benzinga Earnings
·
May 12

Prelude Therapeutics Q1 net loss narrows as expenses fall

Reuters
·
May 12

BRIEF-Prelude Therapeutics Q1 EPS USD -0.13

Reuters
·
May 12

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 12

Prelude Therapeutics Q1 Operating Expenses USD 18.757 Million

THOMSON REUTERS
·
May 12

Prelude Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
May 08

Prelude Therapeutics Initiated at Buy by D. Boral Capital

Dow Jones
·
May 04